


CLAIMS


1. A compound of formula (I):



(I)

wherein:

- 5 R¹ represents hydrogen, C₁₋₄alkyl, -CH₂CO₂H, -CH₂CO₂C₁₋₂alkyl, or -CH₂CONR⁷R⁸;
 R² and R³ independently represent hydrogen, -C₁₋₆alkyl, -C₁₋₃alkylCN, -C₁₋₃alkylCO₂H, -C₁₋₄alkylOC₁₋₄alkyl, -C₁₋₄alkylS(O)_nC₁₋₄alkyl, -C₁₋₄alkylNR¹⁰R¹¹, -C₁₋₃alkylNCO₂C₁₋₄alkyl, -C₁₋₃alkylCONR⁷R⁸, -C₁₋₃alkylCO₂C₀₋₂alkylR⁹, -C₁₋₃alkylCOC₀₋₂alkylR⁹, -C₁₋₃alkylCON(R⁸)C₀₋₂alkylR⁹, -C₁₋₃alkylNCO₂C₀₋₂alkylR⁹, -C₁₋₃alkylNCOC₀₋₂alkylR⁹ or -C₀₋₂alkylR⁹, with the proviso that one of R² and R³ is hydrogen and the other is a substituent other than hydrogen;
 n is an integer between 0 and 2;
 R⁴ and R⁵ together with the nitrogen atom to which they are attached form a morpholino ring;
 10 R⁶ represents a group selected from:



Wherein T_1 and T_2 independently represent CH_2 , NH , S or O with the proviso that when one of T_1 or T_2 represents NH , S or O the other represents CH_2 ;

M represents CH_3 , $-\text{OH}$ or $=\text{O}$;

V represents CH or N ;

5 W represents H , CH_3 , Cl or F ;

X represents Cl , Br , F or $-\text{CH}_3$;

Y represents CH_3 or CF_3 ;

Z represents $-\text{CH}_3$ or F ;

10 R^7 and R^8 are independently hydrogen, C_{1-4} alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O , N or S ;

R^{10} and R^{11} independently represent C_{1-4} alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O , N or S ;

15 R^9 represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from O , N or S , each of which is optionally substituted by 0-2 groups selected from: C_{1-3} alkyl or halogen; and pharmaceutically acceptable derivatives thereof.

20 2. A compound of formula (I) as claimed in claim 1 wherein R^1 represents hydrogen, methyl, $-\text{CH}_2\text{CO}_2\text{C}_{1-2}$ alkyl, or $-\text{CH}_2\text{CONR}^7\text{R}^8$.


25 3. A compound of formula (I) as claims in claim 1 or claim 2 wherein R^2 and R^3 independently represent $-\text{C}_{1-6}$ alkyl, $-\text{C}_{1-3}$ alkylCN, $-\text{C}_{1-4}$ alkylOC $_{1-4}$ alkyl, $-\text{C}_{1-4}$ alkylS(O) $_n$ C_{1-4} alkyl, $-\text{C}_{1-4}$ alkylNR 10 R 11 , $-\text{C}_{1-3}$ alkylCONR 7 R 8 , $-\text{C}_{1-3}$ alkylCO $_2$ C $_{0-2}$ alkylR 9 ,

$-C_{1-3}alkylCON(R^8)C_{0-2}alkylR^9$ or $-C_{0-2}alkylR^9$, with the proviso that one of R^2 and R^3 is hydrogen and the other is a substituent other than hydrogen.

4. A compound of formula (I) as claimed in any of claims 1-3 wherein R^3 represents hydrogen.

5. A compound of formula (I) as claimed in any of claims 1-4 wherein R^6 represents a group selected from:

10



6. A compound as claimed in claim 1 wherein:


R^1 represents hydrogen, methyl, $-CH_2CO_2H$, $-CH_2CO_2C_{1-2}alkyl$, or $-CH_2CONR^7R^8$;

15 R^2 represents $-C_{1-4}alkyl$, $-CH_2CO_2H$, $-CH_2OCH_3$, $-CH(CH_3)OCH_3$, $-CH_2CON(CH_3)_2$, benzyl, $-CH_2CO_2$ -benzyl, $-CH_2CO$ -morpholine, or $-CH_2$ -thiophene;

R^3 represents hydrogen;

R^4 and R^5 together with the nitrogen atom to which they are attached form a morpholino ring;

20 R^6 represents a group selected from:



wherein W represents H, Cl or F;

X represents Cl, Br, F or -CH₃;

Y represents CH₃ or CF₃;

Z represents -CH₃ or F;

R⁷ and R⁸ are independently hydrogen or methyl.

5

7. A compound according to any of claims 1-6 for use in therapy.

8. A pharmaceutical composition comprising a compound according to any of claims 1-6 together with a pharmaceutical carrier and/or excipient.

10



9. Use of a compound according to any of claims 1-6 for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to amelioration by a thrombin inhibitor.

15

10. A method of treating a patient suffering from a condition susceptible to amelioration by a thrombin inhibitor comprising administering a therapeutically effective amount of a compound according to any of claims 1-6.

20

11. A process for preparing a compound of formula (I) which comprises reacting a compound of formula (II) with a compound of formula (III):



25

30